Pharmacopsychiatry 1999; 32(6): 232-234
DOI: 10.1055/s-1999-7960
Original Paper
Georg Thieme Verlag Stuttgart · New York

Citalopram: an Interaction Study with Clomipramine in a Patient Heterozygous for CYP2D6 Genotype

E. Haffen1,2 , P. Vandel1 , F. Broly3 , S. Vandel2 , P. Sechter1 , P. Bizouard1 , P. R. Bechtel2
  • 1Department of Clinical Psychiatry and Medical Psychology
  • 2Department of Clinical Pharmacology, University Hospital of Besançon and 3Laboratory of Biochemistry and Molecular Biology, University Hospital of Lille, France
Further Information

Publication History

Publication Date:
31 December 1999 (online)

A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder. After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed. The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio > 0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A). This case seems to be one of the first descriptions of the clinical relevance of a CYP2D6 heterozygous genotype in a patient treated with antidepressant.

References

Dr. Emmanuel Haffen

Service de Psychiatrie et de Psychologie Médicale

CHU de Besançon

F-25030 cedex, France

Fax: 0381 218817

Email: emmanuel.haffen@ufc-chu.univ-fcomte.fr